Replimune Group, Inc. (REPL) Form 8-K — Aug 14, 2026
Replimune reported that the FDA granted accelerated approval of TUDRIQEV (vusolimogene oderparepvec-wtpg), formerly RP1, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who progressed on a PD-1 antibody-based regimen, with U.S. launch expected within 60 days of the August 14, 2026 report. Fiscal Q1 2027 net loss was $69.8 million, or $0.72 per share, improved from $86.7 million, or $0.95 per share, in the year-ago quarter, with R&D expense of $49.3 million and SG&A of $19.0 million.
Key figures
- Guidance
- Existing cash and short-term investments of $195.3 million plus $141.0 million of net proceeds from the August 2026 common stock issuance expected to fund operations for greater than twelve months, including TUDRIQEV commercialization scale-up.
- Total Assets
- 252447000
- Cash Position
- 195328000
- Rd Expense
- 49277000
- Sga Expense
- 18970000
- Working Capital
- 162395000
- Cash At March31 2026
- 268889000
- Rd Expense Prior Year
- 57843000
- Stockholders Equity
- 105645000
- Us Launch Window Days
- 60
- Sga Expense Prior Year
- 32579000
- Stock Compensation Rd
- 3600000
- Stock Compensation Sga
- 4100000
- Financing Gross Proceeds
- 150000000
- Ignyte3 Primary Endpoint Readout
- 2030
- Reveal Trial Approximate Patients
- 280
- Reveal Phase23 Transition Expected
- Q1 2027
- Net Proceeds August2026 Equity Offering
- 141000000
- Weighted Average Shares Basic And Diluted
- 96864452
Price after filing
Close on the filing date to close N calendar days later (from $14.97). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.